Clinical Trials | September 18, 2025
AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
The medicine was well tolerated, with no unexpected safety issue
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Subscribe To Our Newsletter & Stay Updated
